泰格医药 - Financials

泰格医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	6.6B	7.4B	7.1B	5.2B	3.2B
Revenue Growth %	-10.6%	4.2%	35.9%	63.3%	--
Total Revenue	6.6B	7.4B	7.1B	5.2B	3.2B
Cost Of Revenue	4.4B	4.5B	4.3B	2.9B	1.7B
+Gross Profit	2.2B	2.8B	2.8B	2.3B	1.5B
Gross Margin %	34.0%	38.6%	39.6%	43.6%	47.4%
Total Operating Cost	5.6B	5.6B	5.2B	3.7B	2.4B
Selling Expenses	208.0M	187.0M	150.0M	129.0M	96.6M
Admin Expenses	737.0M	650.0M	630.0M	547.0M	391.0M
Rd Expenses	238.0M	262.0M	235.0M	212.0M	157.0M
Finance Expenses	38.1M	-108.0M	-158.0M	-216.0M	88.1M
+Operating Income	664.0M	2.5B	2.6B	3.7B	2.2B
Operating Margin %	10.1%	33.7%	36.4%	70.9%	69.6%
Non Operating Income	5.1M	13.5M	11.3M	6.3M	9.5M
Non Operating Expenses	5.0M	11.9M	8.3M	18.7M	13.1M
Investment Income	167.0M	338.0M	103.0M	312.0M	284.0M
Fair Value Change Income	-502.0M	353.0M	536.0M	1.8B	1.1B
Asset Disposal Income	3.6M	-188,100	-86,600	-530,900	-886,100
Asset Impairment Loss	-1.3M	29.7M	2.4M	12.9M	-5.4M
Other Income	36.9M	34.4M	40.0M	18.5M	20.0M
Income Before Tax	664.0M	2.5B	2.6B	3.7B	2.2B
Income Tax	217.0M	339.0M	314.0M	293.0M	190.0M
+Net Income	448.0M	2.1B	2.3B	3.4B	2.0B
Net Margin %	6.8%	29.1%	32.1%	65.1%	63.6%
Net Income Attributable	405.0M	2.0B	2.0B	2.9B	1.8B
Minority Interest	42.7M	125.0M	265.0M	518.0M	279.0M
Eps Basic	0.47	2.34	2.32	3.31	2.20
Eps Diluted	0.47	2.34	2.32	3.30	2.19

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	2.1B	7.4B	7.9B	8.5B	10.1B
Trading Financial Assets	74.9M	42.1M	24.9M	29.2M	26.0M
Accounts Receivable	1.4B	1.3B	1.0B	809.0M	491.0M
Notes Receivable	6.0M	214,600	6.0M	6.9M	4.8M
Notes And Accounts Receivable	1.4B	1.3B	1.0B	816.0M	496.0M
Prepayments	102.0M	56.5M	59.1M	59.3M	28.2M
Inventory	32.0M	23.4M	22.2M	6.1M	4.7M
Total Current Assets	6.3B	11.3B	11.1B	10.9B	11.6B
Long Term Equity Investment	3.4B	3.0B	1.8B	739.0M	60.3M
Fixed Assets	--	639.0M	566.0M	438.0M	300.0M
Fixed Assets Total	778.0M	639.0M	566.0M	438.0M	300.0M
Construction In Progress	--	324.0M	186.0M	217.0M	54.8M
Construction In Progress Total	421.0M	324.0M	186.0M	217.0M	54.8M
Intangible Assets	337.0M	371.0M	338.0M	251.0M	142.0M
Long Term Deferred Expenses	210.0M	214.0M	211.0M	35.2M	33.4M
Total Non Current Assets	22.4B	18.3B	16.3B	12.9B	7.9B
Total Assets	28.7B	29.7B	27.4B	23.7B	19.5B
Short Term Borrowings	1.9B	2.0B	1.8B	492.0M	--
Accounts Payable	257.0M	249.0M	158.0M	126.0M	101.0M
Advance Receipts	--	--	--	--	--
Contract Liabilities	791.0M	680.0M	940.0M	790.0M	485.0M
Total Current Liabilities	3.7B	4.1B	3.7B	2.4B	1.1B
Long Term Borrowings	324.0M	434.0M	245.0M	--	--
Total Non Current Liabilities	945.0M	1.1B	1.0B	723.0M	508.0M
Total Liabilities	4.6B	5.2B	4.8B	3.1B	1.6B
Paid In Capital	865.0M	872.0M	872.0M	872.0M	872.0M
Capital Reserve	10.8B	11.7B	11.9B	11.9B	12.0B
Surplus Reserve	437.0M	437.0M	392.0M	317.0M	222.0M
Retained Earnings	8.7B	8.8B	7.3B	5.8B	3.3B
Minority Equity	3.4B	3.4B	3.1B	2.5B	1.7B
Equity Attributable	20.7B	21.0B	19.6B	18.1B	16.1B
Total Equity	24.1B	24.5B	22.7B	20.6B	17.9B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	6.8B	6.8B	6.6B	5.0B	3.4B
Tax Refunds Received	615,200	10.0M	35.0M	5.4M	4.1M
Total Operating Cash Inflow	7.0B	7.1B	6.9B	5.3B	3.5B
Cash Paid For Goods	2.0B	2.0B	2.2B	1.5B	807.0M
Cash Paid To Employees	3.1B	2.9B	2.5B	1.8B	1.3B
Taxes Paid	525.0M	655.0M	630.0M	327.0M	245.0M
Total Operating Cash Outflow	5.9B	5.9B	5.6B	3.9B	2.5B
Operating Cash Flow	1.1B	1.1B	1.4B	1.4B	999.0M
Total Investing Cash Inflow	2.2B	1.3B	581.0M	1.2B	1.1B
Total Investing Cash Outflow	6.9B	2.8B	3.4B	4.0B	3.4B
Investing Cash Flow	-4.7B	-1.5B	-2.8B	-2.8B	-2.4B
Cash From Borrowings	3.4B	3.2B	3.4B	492.0M	1.2B
Dividends And Interest Paid	642.0M	590.0M	492.0M	284.0M	271.0M
Debt Repayments	3.9B	2.5B	1.8B	--	2.1B
Total Financing Cash Inflow	3.6B	3.6B	3.8B	781.0M	12.4B
Total Financing Cash Outflow	5.3B	3.6B	3.0B	944.0M	3.1B
Financing Cash Flow	-1.7B	-7.8M	809.0M	-163.0M	9.3B
Net Change In Cash	-5.4B	-383.0M	-596.0M	-1.6B	7.9B
Ending Cash Balance	2.0B	7.4B	7.8B	8.4B	10.0B
Capex	357.0M	314.0M	449.0M	369.0M	156.0M